AAV-SLB101 – UF Innovate

Solid Biosciences Announces Licensing Agreement With Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (Globe Newswire)

sooyoungryu — Mon, 17 Nov 2025 13:41:11 +0000

Solid Biosciences Inc., which acquired UF startup AavantiBio, announced a non-exclusive worldwide license and collaboration agreement with Andelyn Biosciences, a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101.

Under the terms of the agreement, Solid grants Andelyn a non-exclusive worldwide license to provide its gene therapy clients with access to utilize AAV-SLB101 in combination with Andelyn’s suspension and adherent modular platform process, the AAV Curator® Platform, which brings a modular approach to gene therapy CMC processes by optimizing manufacturing and using configurable materials. Specific financial terms of the agreement have not been disclosed.

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (Solid Biosciences)

sooyoungryu — Tue, 30 Sep 2025 13:42:32 +0000

Solid Biosciences Inc., which acquired UF startup AavantiBio, announced a non-exclusive worldwide license and collaboration agreement with Kinea Bio for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101, for the development and commercialization of KNA-155, an investigational dual AAV gene therapy targeting dysferlinopathy, a form of limb-girdle muscular dystrophy type 2B/R2 (LGMD2B/R2).

Under the terms of the agreement, Solid granted Kinea Bio a non-exclusive worldwide license to utilize AAV-SLB101 as the delivery backbone for KNA-155, which is advancing into IND-enabling preclinical activities. In return, Solid receives an upfront fee and is eligible for additional payments upon the achievement of certain development and sales milestones and tiered royalties on net sales.